PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70) 14

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
PC/SJB/P1047PC		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/GB00/00585	18/02/2000	18/02/1999
International Patent Classification (IPC) or national classification and IPC G01N33/68		
Applicant UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 7 sheets, including this cover sheet.

   ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☐ Priority
   - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☐ Certain documents cited
   - VII ☒ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
11/09/2000	10.05.2001
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Goetz, M Telephone No. +49 89 2399 8697

Form PCT/IPEA/409 (cover sheet) (January 1994)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/00585

I. Basis of the report

1. With regard to the **elements** of the international application *(Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17))*:
Description, pages:

1-51	as originally filed

Claims, No.:

1-31	as originally filed

Drawings, sheets:

1/22-22/22	as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

   These elements were available or furnished to this Authority in the following language: , which is:

   - ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
   - ☐ the language of publication of the international application (under Rule 48.3(b)).
   - ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

   - ☐ contained in the international application in written form.
   - ☐ filed together with the international application in computer readable form.
   - ☐ furnished subsequently to this Authority in written form.
   - ☐ furnished subsequently to this Authority in computer readable form.
   - ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
   - ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

   - ☐ the description, pages:
   - ☐ the claims, Nos.:

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 30, 31.

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 30, 31.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Yes: Claims 4, 6, 12, 13, 18, 19, 21 - 23, 25

	No:	Claims	1 - 3, 5, 7 - 11, 14 - 17, 20, 24, 26 - 29
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1 - 29
Industrial applicability (IA)	Yes:	Claims	1 - 29
	No:	Claims	

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

As no search has been carried out for claims 30 and 31, this IPER is only established for claims 1 - 29 (see also section VIII).

Re Item V

Reasoned statement under Rule 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Reference is made to the following document/s/:

   D1: WO98/30715
   D2: WO97/20931
   D3: Mol.Pharmacology 51, 1997, pp. 177 - 184 (cited in the application)
   D4: Mol.Pharmacology 56, 1999, pp. 1182-1191

2. **D1** discloses chimeric receptor/GFP polypeptides (e.g. ion channel/GFP chimera), the nucleic acids encoding them, cell lines containing them, as well as in vitro and in vivo assays for determining the effect of a test compound on a cell bearing the receptor/GFP construct by measuring the modification in e.g. the fluorescence. More particularly, the embodiments recited on page 2/line 15 - page 3/line 4, page 3/line 30 - page4/line2, page 5/line 5 - page 6/line 25, page 8/line 24 - page 9/line 15, page 11/lines 9 - 21, page 13/line 13 - page 14/line 11, page 24/line 27 - page 26/line 13, examples 1 and 2, claims 1 - 51 and Fig. 1B, would appear to anticipate the subject-matter of present claims 1 - 3, 5, 7 - 11, 14 - 17, 20, 24, 26 - 29 which do not therefore meet the requirements according to Art. 33(2) PCT.

3. It appears that most of the claimed subject-matter does not involve an inventive step for the following reasons:

3.1. **D2** describes a method for the detection of agonists/antagonists to steroid receptors which uses the same methodology as presently claimed, i.e. a fusion protein construct comprising a steroid receptor linked to e.g. GFP (see **D2**, page 6/line 7 - page 9/line 27, page 15/line 15 - page 16/line 13, page 19/line 4 - page 21/line 2, page 30/line 21 - page 32/line 12, Fig. 3A.

The difference between **D2** and the presently claimed subject-matter resides in the natures of the receptor half of the fusion protein which is a cytosolic steroid receptor in **D2** and a membrane receptor in the present application.

3.2. However, as the skilled person would know from **D1** that a cell-based assay can be carried out using a chimeric receptor/GFP polypeptide (e.g. ion channel/GFP chimera), there would be no obstacle to use the methodology according to **D2** with the receptor/GFP fusion constructs of **D1.**

3.3. Moreover, document **D3**, as discussed in the present description, already established the basic properties of an assay system comprising HEK693 cell membranes with a transiently expressed β_2-AR/GFP fusion protein (see **D3**, page 177/Summary, page 178/left column/2nd full paragraph until "Experimental procedures", page 178/right column/"Binding studies" and the "Discussion" section on page 183).

Having knowledge of the information provided by **D3**, the skilled person would undoubtly be able to use e.g. the β_2-AR/GFP fusion protein of **D3** in the methodology exposed in either **D1** or **D2**, and would thus arrive in an obvious manner at the presently claimed subject-matter.

3.4. Since it appears that none of present claims 1 - 29 involves an inventive step, the said claims do not meet the requirements according to Art. 33(3) PCT.

4. Should the presently claimed priority of GB application 9903767 not be valid, it would appear that **D4** anticipates or renders obvious most of the claimed subject-matter.

Re Item VII

Certain defects in the international application

Contrary to Rule 5.1 (a)(ii) PCT, the teaching provided by documents **D1** and **D2** has not at least briefly been discussed in the description.

Re Item VIII

Certain observations on the international application

Since present claims 30 and 31 relate to an extremely large number of possible compounds, including a plethora of yet unknown, thus hypothetical agonists/antagonists, these claims lack support and/or disclosure within the meaning of Articles 5 and 6 PCT.

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Assistant Commissioner for Patents
United States Patent and Trademark Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 17 October 2000 (17.10.00)	
International application No. PCT/GB00/00585	Applicant's or agent's file reference MGH/PC/P10407PC
International filing date (day/month/year) 18 February 2000 (18.02.00)	Priority date (day/month/year) 18 February 1999 (18.02.99)

Applicant

MILLIGAN, Graeme et al

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

11 September 2000 (11.09.00)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer S. Mafla
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

GB0000585

Form PCT/IB/331 (July 1992)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	**FOR FURTHER ACTION** see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
MGH/PC/P10407PC		
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/GB 00/ 00585	18/02/2000	18/02/1999

Applicant

UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

a. With regard to the **language,** the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

[ ] the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

[ ] contained in the international application in written form.

[ ] filed together with the international application in computer readable form.

[ ] furnished subsequently to this Authority in written form.

[ ] furnished subsequently to this Authority in computer readble form.

[ ] the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

[ ] the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. [X] **Certain claims were found unsearchable** (See Box I).

3. [ ] **Unity of invention is lacking** (see Box II).

4. With regard to the **title,**

[ ] the text is approved as submitted by the applicant.

[X] the text has been established by this Authority to read as follows:

RECEPTOR ASSAY FOR DETECTING AN EFFECT TEST COMPOUNDS HAVE ON A PARTICULAR MEMBRANE RECEPTOR

5. With regard to the **abstract,**

[X] the text is approved as submitted by the applicant.

[ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. _____

[ ] as suggested by the applicant.

[ ] because the applicant failed to suggest a figure.

[ ] because this figure better characterizes the invention.

[X] None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 00/00585

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 30,31
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 30,31

Present claims 30-31 relate to an extremely large number of possible compounds, including a plethora of yet unknown, thus hypothetical agonists/antagonists. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only some of the compounds claimed having an agonist/antagonist activity on a membrane receptor. In the present case, claims 30 and 31 so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those compounds as recited in the examples.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International Application No
PCT [redacted] 00/00585

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/68 C12N15/62 C07K14/72

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N C12N C12P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 30715 A (ISACOFF EHUD Y ;SIEGAL MICAH S (US); UNIV CALIFORNIA (US); CALIFOR) 16 July 1998 (1998-07-16) page 2, line 15 -page 3, line 4 page 3, line 30 -page 4, line 2 page 5, line 5 -page 6, line 25 page 8, line 24 -page 9, line 15 page 11, line 9-21 page 13, line 13 -page 14, line 11 page 24, line 27 -page 26, line 13 claims 1-51; figure 1B; examples 1,2	1-3,5, 7-11, 14-17, 20,24, 26-31
Y		2,6,12, 13,18, 19, 21-23,25

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
14 November 2000	17. 11. 00

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Goetz, M

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 20931 A (US HEALTH ;HTUN HAN (US); HAGER GORDON L (US)) 12 June 1997 (1997-06-12) page 6, line 7 -page 9, line 27 page 15, line 15 -page 16, line 13 page 19, line 4 -page 21, line 2 page 30, line 21 -page 32, line 12 figure 3A	1-29
Y	BARAK L S ET AL: "Internal trafficking and surface mobility of a functionally intact beta2-adrenergic receptor-green fluorescent protein conjugate" MOLECULAR PHARMACOLOGY,US,BALTIMORE, MD, vol. 2, no. 51, 1 February 1997 (1997-02-01), pages 177-184, XP002076352 ISSN: 0026-895X cited in the application	1-29
X	the whole document	30,31
X,P	DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; December 1999 (1999-12) MCLEAN ALISON J ET AL: "Visualizing differences in ligand regulation of wild-type and constitutively active mutant beta2-adrenoceptor-green fluorescent protein fusion proteins." Database accession no. PREV200000102798 XP002152838 abstract & MOLECULAR PHARMACOLOGY, vol. 56, no. 6, December 1999 (1999-12), pages 1182-1191, ISSN: 0026-895X	1-29

2

INTERNATIONAL SEARCH REPORT

Informa[redacted] patent family members

International Application No
PC[redacted] 00/00585

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9830715 A	16-07-1998	AU 5090498 A	03-08-1998
WO 9720931 A	12-06-1997	AU 1283497 A	27-06-1997
		CA 2239951 A	12-06-1997

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference *(if desired) (12 characters maximum)* MGH/PC/P10407PC

Box No. I TITLE OF INVENTION

RECEPTOR ASSAY

Box No. II APPLICANT

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW
Gilbert Scott Building
University Avenue
Glasgow G12 8QQ
UNITED KINGDOM

☐ This person is also inventor.

Telephone No.

Facsimile No.

Teleprinter No.

State *(that is, country)* of nationality: GB

State *(that is, country)* of residence: GB

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

MILLIGAN GRAEME
2/1 64 Lauderdale Gardens
Hyndland
Glasgow G12 9QW
UNITED KINGDOM

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only *(If this check-box is marked, do not fill in below.)*

State *(that is, country)* of nationality: GB

State *(that is, country)* of residence: GB

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: ☐ agent ☐ common representative

Name and address:
McCALLUM, William Potter; MacDOUGALL, Donald Carmichael; SZCZUKA, Jan Tymoteusz; NAISMITH, Robert Stewart; HORNER,Martin Grenville, SHANKS, Andrew; NEWELL, Campbell; KERR, Sheila Agnes Fife; MORELAND, David; GODWIN, Edgar James; all of
CRUIKSHANK & FAIRWEATHER, 19 ROYAL EXCHANGE SQUARE,
GLASGOW G1 3AE, UNITED KINGDOM (GB)

Telephone No. 0141 221 5767

Facsimile No. 0141 221 7739

Teleprinter No.

☐ **Address for correspondence:** Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

REES EDWARD STEPHEN
30 Youngs Rise
Welwyn Garden City
Herts AL8 6RU
UNITED KINGDOM

This person is:

- [ ] applicant only
- [X] applicant and inventor
- [ ] inventor only *(If this check-box is marked, do not fill in below.)*

State *(that is, country)* of nationality: GB

State *(that is, country)* of residence: GB

This person is applicant for the purposes of:

- [ ] all designated States
- [ ] all designated States except the United States of America
- [X] the United States of America only
- [ ] the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

This person is:

- [ ] applicant only
- [ ] applicant and inventor
- [ ] inventor only *(If this check-box is marked, do not fill in below.)*

State *(that is, country)* of nationality:

State *(that is, country)* of residence:

This person is applicant for the purposes of:

- [ ] all designated States
- [ ] all designated States except the United States of America
- [ ] the United States of America only
- [ ] the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

This person is:

- [ ] applicant only
- [ ] applicant and inventor
- [ ] inventor only *(If this check-box is marked, do not fill in below.)*

State *(that is, country)* of nationality:

State *(that is, country)* of residence:

This person is applicant for the purposes of:

- [ ] all designated States
- [ ] all designated States except the United States of America
- [ ] the United States of America only
- [ ] the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

This person is:

- [ ] applicant only
- [ ] applicant and inventor
- [ ] inventor only *(If this check-box is marked, do not fill in below.)*

State *(that is, country)* of nationality:

State *(that is, country)* of residence:

This person is applicant for the purposes of:

- [ ] all designated States
- [ ] all designated States except the United States of America
- [ ] the United States of America only
- [ ] the States indicated in the Supplemental Box

- [ ] Further applicants and/or (further) inventors are indicated on another continuation sheet.

Box No.V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) *(mark the applicable check-boxes: at least one must be marked)*:

Regional Patent

☒ **AP** **ARIPO Patent:** **GH** Ghana, **GM** Gambia, **KE** Kenya, **LS** Lesotho, **MW** Malawi, **SD** Sudan, **SL** Sierra Leone, **SZ** Swaziland, **TZ** United Republic of Tanzania, **UG** Uganda, **ZW** Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT

☒ **EA** **Eurasian Patent:** **AM** Armenia, **AZ** Azerbaijan, **BY** Belarus, **KG** Kyrgyzstan, **KZ** Kazakhstan, **MD** Republic of Moldova, **RU** Russian Federation, **TJ** Tajikistan, **TM** Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT

☒ **EP** **European Patent:** **AT** Austria, **BE** Belgium, **CH and LI** Switzerland and Liechtenstein, **CY** Cyprus, **DE** Germany, **DK** Denmark, **ES** Spain, **FI** Finland, **FR** France, **GB** United Kingdom, **GR** Greece, **IE** Ireland, **IT** Italy, **LU** Luxembourg, **MC** Monaco, **NL** Netherlands, **PT** Portugal, **SE** Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT

☒ **OA** **OAPI Patent:** **BF** Burkina Faso, **BJ** Benin, **CF** Central African Republic, **CG** Congo, **CI** Côte d'Ivoire, **CM** Cameroon, **GA** Gabon, **GN** Guinea, **GW** Guinea-Bissau, **ML** Mali, **MR** Mauritania, **NE** Niger, **SN** Senegal, **TD** Chad, **TG** Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT *(if other kind of protection or treatment desired, specify on dotted line)* .....

National Patent *(if other kind of protection or treatment desired, specify on dotted line)*:

☒ **AE** United Arab Emirates
☒ **AL** Albania
☒ **AM** Armenia
☒ **AT** Austria
☒ **AU** Australia
☒ **AZ** Azerbaijan
☒ **BA** Bosnia and Herzegovina
☒ **BB** Barbados
☒ **BG** Bulgaria
☒ **BR** Brazil
☒ **BY** Belarus
☒ **CA** Canada
☒ **CH and LI** Switzerland and Liechtenstein
☒ **CN** China
☒ **CR** Costa Rica
☒ **CU** Cuba
☒ **CZ** Czech Republic
☒ **DE** Germany
☒ **DK** Denmark
☒ **DM** Dominica
☒ **EE** Estonia
☒ **ES** Spain
☒ **FI** Finland
☒ **GB** United Kingdom
☒ **GD** Grenada
☒ **GE** Georgia
☒ **GH** Ghana
☒ **GM** Gambia
☒ **HR** Croatia
☒ **HU** Hungary
☒ **ID** Indonesia
☒ **IL** Israel
☒ **IN** India
☒ **IS** Iceland
☒ **JP** Japan
☒ **KE** Kenya
☒ **KG** Kyrgyzstan
☒ **KP** Democratic People's Republic of Korea
☒ **KR** Republic of Korea
☒ **KZ** Kazakhstan
☒ **LC** Saint Lucia
☒ **LK** Sri Lanka
☒ **LR** Liberia
☒ **LS** Lesotho
☒ **LT** Lithuania
☒ **LU** Luxembourg
☒ **LV** Latvia
☒ **MA** Morocco
☒ **MD** Republic of Moldova
☒ **MG** Madagascar
☒ **MK** The former Yugoslav Republic of Macedonia
☒ **MN** Mongolia
☒ **MW** Malawi
☒ **MX** Mexico
☒ **NO** Norway
☒ **NZ** New Zealand
☒ **PL** Poland
☒ **PT** Portugal
☒ **RO** Romania
☒ **RU** Russian Federation
☒ **SD** Sudan
☒ **SE** Sweden
☒ **SG** Singapore
☒ **SI** Slovenia
☒ **SK** Slovakia
☒ **SL** Sierra Leone
☒ **TJ** Tajikistan
☒ **TM** Turkmenistan
☒ **TR** Turkey
☒ **TT** Trinidad and Tobago
☒ **TZ** United Republic of Tanzania
☒ **UA** Ukraine
☒ **UG** Uganda
☒ **US** United States of America
☒ **UZ** Uzbekistan
☒ **VN** Viet Nam
☒ **YU** Yugoslavia
☒ **ZA** South Africa
☒ **ZW** Zimbabwe

Check-boxes reserved for designating States which have become party to the PCT after issuance of this sheet:

☐ .....
☐ .....

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. *(Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)*

Box No. VI PRIORITY CLAIM ☐ Further priority claims are indicated in the Supplemental Box.

Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is: national application: country	regional application:* regional Office	international application: receiving Office
item (1) 18/02/1999	GB9903767.3	UNITED KINGDOM		
item (2)				
item (3)				

☒ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) *(only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office)* identified above as item(s): (1)

* *Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.*

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) *(if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used)* : ISA /

Request to use results of earlier search; reference to that search *(if an earlier search has been carried out by or requested from the International Searching Authority)*:

Date *(day·month·year)* Number Country *(or regional Office)*

Box No. VIII CHECK LIST; LANGUAGE OF FILING

This international application contains the following **number of sheets**:

request	:	4
description (excluding sequence listing part)	:	51
claims	:	6
abstract	:	1
drawings	:	22
sequence listing part of description	:	
Total number of sheets	:	84

This international application is **accompanied by** the item(s) marked below:

1. ☐ fee calculation sheet
2. ☐ separate signed power of attorney
3. ☐ copy of general power of attorney; reference number, if any:
4. ☐ statement explaining lack of signature
5. ☐ priority document(s) identified in Box No. VI as item(s):
6. ☐ translation of international application into (language):
7. ☐ separate indications concerning deposited microorganism or other biological material
8. ☐ nucleotide and/or amino acid sequence listing in computer readable form
9. ☐ other *(specify)*:

Figure of the drawings which should accompany the abstract:

Language of filing of the international application:

Box No. IX SIGNATURE OF APPLICANT OR AGENT

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

MARTIN G. ~~HORNER~~.

For receiving Office use only

1. Date of actual receipt of the purported international application:	2. Drawings: ☐ received: ☐ not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):	
5. International Searching Authority (if two or more are competent): ISA /	6. ☐ Transmittal of search copy delayed until search fee is paid.

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

NK

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : G01N 33/68, C07K 14/705

A2

(11) International Publication Number: **WO 00/49416**

(43) International Publication Date: 24 August 2000 (24.08.00)

(21) International Application Number: PCT/GB00/00585

(22) International Filing Date: 18 February 2000 (18.02.00)

(30) Priority Data:
9903767.3 18 February 1999 (18.02.99) GB

18 Aug 01 | 30 mos

(71) Applicant *(for all designated States except US)*: UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW [GB/GB]; Gilbert Scott Building, University Avenue, Glasgow G12 8QQ (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: MILLIGAN, Graeme [GB/GB]; 2/1 64 Lauderdale Gardens, Hyndland, Glasgow G12 9QW (GB). REES, Edward, Stephen [GB/GB]; 30 Youngs Rise, Welwyn Garden City, Herts AL8 6RU (GB).

(74) Agents: McCALLUM, William, Potter et al.; Cruikshank & Fairweather, 19 Royal Exchange Square, Glasgow G1 3AE (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: RECEPTOR ASSAY

(57) Abstract

The present invention relates to receptor/reporter fusion protein based assays for detecting an effect test compounds have on a particular membrane receptor, as well as to receptor/reporter fusion proteins for use in such assays and compounds identified by the assays as having interesting/useful effects. Suitable membrane receptors are growth factor receptors, cytokine receptors, ion channels and integrins including any subtypes, mutants, homologs and chimeric forms of such receptors. The assay is particularly suited to studying G–protein coupled receptors (GPCRs).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

Receptor Assay

The present invention relates to receptor/reporter fusion protein based assays for detecting an effect test compounds have on a particular membrane receptor, as well as to receptor/reporter fusion proteins for use in such assays and compounds identified by the assays as having interesting/useful effects.

Traditional protocols for the measurement of ligand activity at receptors such as G-protein coupled receptors (GPCRs) have relied upon a number of biochemical techniques. These include radioligand binding analysis in which the ability of a test compound to displace the binding of a known radioligand is determined, and a number of functional assays in which the ability of a test compound to activate or inhibit a specific signal transduction event is measured.

Functional assays of ligand activity at GPCRs expressed in mammalian cells include the measurement of the rate of guanine nucleotide exchange at the activated G-protein alpha sub-unit (Wise *et al.*, 1997), the measurement of the changes in the level of one of a plethora of intracellular second messenger metabolites, such as cAMP, calcium, or inositol phosphates (Guderman *et al.*, 1996), or the activation or inhibition of an ion channel (Walker and de Waard, 1998). In recent years these assays have been supplemented by the development of reporter gene systems for the study of GPCR signal transduction (Stratowa *et al.*, 1995; Alam and Cook, 1990), as well as a number of other

mammalian cell, yeast or Xenopus melanophore based assays.

The Aequorea victoria photoprotein GFP (Green Fluorescent Protein) is a 238 amino acid protein that emits green light with an emission maximum of 509nm upon fluorescent excitation at 488nm. Unlike other bioluminescent reporter proteins no additional substrates or cofactors are required for light emission (Chen *et al.*, 1995). GFP fluorescence is stable and has been measured non-invasively in living cells of many species including mammalian cells, drosophila, *C. elegans*, yeast and *E. coli*. GFP fluorescence can be detected by fluorimetry, by FACS and by microscopy. As there is no assay reagent or assay protocol the attractiveness of GFP as a reporter protein is cost, together with the speed and simplicity of the assay (Chalfie and Kain, 1998).

The availability of the cDNA sequence for GFP has resulted in the generation and characterisation of several GFP mutants with enhanced fluorescence emission. Mutation of the serine at amino acid 65 to threonine has resulted in the generation of a protein with a 6-fold increase in the intensity of fluorescence emission (Haas *et al.*, 1996). Furthermore, the presence of the Ser65Thr and the mutation of the phenylalanine residue at position 64 to leucine has resulted in a 35-fold increase in fluorescence intensity (Haas *et al.*, 1996). In addition, a number of novel mutants of GFP have also been identified with altered excitation or emission characteristics. For example mutation of the tyrosine residue at position 66 to

histidine has generated a protein with blue fluorescence emission, the so-called blue fluorescent protein (BFP) with a λ_{max} for excitation of 458 nm and for emission of 480 nm (Chalfie and Kain, 1998). These and many other variants of GFP protein are now commercially available.

GFP has been widely used in fusion proteins to assess protein trafficking, and subcellular localisation of recombinantly expressed proteins (Wang and Hazelrigg, 1994). Recently, a number of groups have described the creation and use of GPCR-GFP fusion proteins to monitor receptor internalisation and recycling following agonist treatment. For example a fusion protein between the β_2-adrenoceptor and GFP has been used to monitor receptor expression, localisation at the plasma membrane and internalisation following agonist stimulation (Barak *et al.*, 1997).

In recent years a number of studies have described the introduction of specific mutations into GPCRs that result in agonist-independent activation of a signal transduction cascade by the mutant GPCR when expressed in mammalian cells (Scheer and Cotecchia, 1997, Leurs *et al.*, 1998). This phenomena has been described as constitutive activity, and such mutant receptors termed constitutively active mutant (CAM) receptors. Such experiments have generally been considered to shed light on possible structural alterations in the GPCR which occur upon agonist-binding to result in activation of a cognate G protein and thus regulation of the activity of downstream effector enzymes.

Such strategies appear to possess validity because, in the case of the β_2-adrenoceptor for example, one of the structural modifications associated with agonist binding to the wild type GPCR is a movement of transmembrane helix 6 which can be measured by the positioning of residue Cys^{285} (Gether *et al.*, 1997a). In a CAM form of this GPCR this same Cys residue is closer to the ligand binding pocket than in the ligand-unoccupied wild type receptor (Javitch *et al.*, 1997).

Perhaps the most studied of the CAM GPCRs is a form of the human β_2-adrenoceptor in which a short segment of the C-terminal region of the third intracellular loop was replaced with the corresponding region from the α_{1B}-adrenoceptor (Samama *et al.*, 1993, Samama *et al.*, 1994).

The present invention is based in part on investigations on the possibility of developing the phenomena of ligand stabilisation of a CAM GPCR to lead to an increase in receptor number at the cell surface, as an assay system for ligand activity at such a receptor. As a model system the present applicants describe the stability and regulation, by a series of inverse agonist ligands, of a CAM β_2-adrenoceptor which has had the 27kDa GFP added in-frame at the C-terminal. The present applicants have measured ligand efficacy by determining the ability of each ligand to cause a change in the cellular distribution of the GPCR-GFP fusion protein or to cause an alteration in total cellular fluorescence. Furthermore the present applicants have examined the effect of a series of specific

agonists on the cellular distribution, and total cellular fluorescence, of cells expressing a WT β_2-adrenoceptor/GFP fusion protein as a screening system for agonist ligands at this receptor.

Thus, in a first aspect the present invention provides an assay for detecting an effect a compound has on a membrane receptor/reporter fusion protein, comprising the steps of:

a) adding the compound to a cell comprising said membrane receptor/reporter fusion protein; and

b) detecting any change of said receptor/reporter fusion protein.

Typically the assay may be used to screen compounds for their effect on particular membrane receptors. Compounds identified as having an effect on a particular membrane receptor may be useful, for example, in modulating the activity of wild type and/or mutant membrane receptors; may be used in elaborating the biological function of particular membrane receptors; and/or may be used in screens for identifying compounds that disrupt normal membrane receptor interactions, or can in themselves disrupt such interactions.

The assay is particularly suited for the detection of compounds which serve as inverse agonists, antagonists or agonists of the membrane receptor. The term inverse agonist is understood to mean a compound which when it binds to a receptor, selectively stabilises and thus enriches the proportion of a receptor in a conformation or

conformations incapable of inducing a downstream signal. Agonist is understood to mean a compound which when it binds to a receptor selectively stabilises and thus enriches the proportion of the receptor in a conformation or conformations capable of inducing a downstream signal. Antagonist is understood to mean a compound which when it binds to a receptor has no selective ability to enrich either active or inactive conformations and thus does not alter the equilibrium between them.

The term compound is understood to include chemicals as well as peptides and/or proteins.

The present invention also therefore relates to inverse agonists, antagonists or agonists of receptor proteins identified using the assays according to the present invention and to the use of such agonists, antagonists or agonists in study receptor function, or therapy.

The assay may be applied to a variety of membrane receptors, such as growth factor receptors, cytokine receptors, ion channels and integrins. The assay is however particularly suited to studying the effects of compounds on G-protein coupled receptors (GCPRs).

The term receptor as used herein is intended to encompass subtypes of the named receptors, and mutants, such as constitutively active mutants, homologs thereof, and chimeric receptors including the nucleic acid encoding such receptors. Chimeric receptors as used herein refers to receptors which may be formed comprising parts of

mammalian receptors found from different sources.

Generally speaking any G protein coupled receptor, and the DNA sequences encoding such receptors may be used in assays of the present invention. Typical G protein coupled receptors are for example dopamine receptors, muscarinic cholinergic receptors, α-adrenergic receptors, β-adrenergic receptors, opiate receptors, cannabinoid receptors and serotonin receptors.

The membrane receptors mentioned herein are typically modified by the fusion of a reporter protein to the receptor. Typically nucleic acid encoding the reporter protein, such as Green Fluorescent Protein (GFP) may be fused in-frame to an end, that is the 5' or 3' end, of a gene encoding the particular receptor. In this manner, on expression of the gene, the reporter protein is functionally expressed and fused to the N-terminal or C-terminal end of the receptor. Modification of the receptor is such that the functionality of the membrane receptor remains substantially unaffected by fusion of the reporter protein to the receptor.

As mentioned previously GFP emits green light upon fluorescent excitation. Detection of this green light may be carried out for example by fluorimetry, FACS and by microscopy techniques well known to one skilled in the art. In this manner localisation and/or quantification of a membrane receptor may be determined.

The present invention in a further aspect therefore also relates to novel membrane receptor/reporter fusion proteins for use in the disclosed assays and their nucleic acid constructs, such as a constitutively active β_2-adrenoreceptor/GFP fusion protein and β_2-adrenoreceptor/GFP gene fusion. Although it might be anticipated that attachment of the GFP 27KDa polypeptide to the end of a receptor such as GPCR might significantly interfere with receptor function, it has been previously reported that GPCRs modified in this manner display unaltered pharmacology and remain able to interact with G proteins to initiate second messenger regulation. For example a receptor/reporter fusion protein may be provided in which the C-terminus of a receptor is linked directly to the N-terminus of a reporter protein. Minor modification may be carried out to the protein sequence, for example, an epitope tag may be added to the N-terminus of the receptor and/or the terminal methionine of the reporter gene removed. Many such modifications may be envisaged by the skilled addressee providing the functionality of the receptor/reporter fusion protein remains substantially uneffected.

The nucleic acid constructs of the present invention comprise nucleic acid, typically DNA, encoding the particular receptor to which is fused, in-frame, the appropriate gene encoding the reporter protein. Generally speaking the nucleic acid constructs are expressed in the cells being tested by means of an expression vector.

Typically, although not exclusively the cells are of mammalian origin and the expression vector chosen is one which is suitable for expression in the particular cell type.

An expression vector is a replicable DNA construct in which the nucleic acid is operably linked to suitable control sequences capable of effecting the expression of the membrane receptor/reporter fusion in the particular cell. Typically control sequences may include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and sequences which control the termination of transcription and/or translation. Typical expression vectors may include for example plasmids, bacteriophages or viruses and such vectors may integrate into the host's genome or replicate automonously in the particular cell.

In order for the particular cell to express the receptor/reporter fusion protein the cell must be transformed by the appropriate expression vector. "Transformation", as used herein, refers to the introduction of a heterologous polynucleotide fragment into a host cell, irrespective of the method used, for example direct uptake, transfection or transduction.

The present invention therefore also relates to cells which have been transformed by nucleic acid constructs comprising receptor/reporter fusions of the present invention and express the receptor/reporter fusion protein.

In addition to the Green Fluorescent Protein (GFP) similar receptor/reporter fusion protein constructs may be made using other coloured varients of GFP such as the Blue Fluorescent Protein, the Yellow Fluorescent Protein or the Cyan Fluorescent Protein (Chalfie and Kain, 1998).

Similar receptor/reporter fusions may also be generated using other reporter proteins such as firefly (*Photinus pyralis*) luciferase (Alam and Cook, 1990). The construction of a GPCR/firefly luciferase fusion would enable the detection of compound activity using firefly luciferase activity as the read-out with detection for example in a microplate luminometer or using a CCD imaging system. Firefly luciferase assays are highly sensitive and are amenable to assay in miniturised plate formats and for detection by CCD imaging (Suto and Ignar, 1997). In addition to GFP or firefly luciferase similar receptor/reporter fusions may be generated using any reporter enzyme including *Renilla reniformis* (sea pansy) luciferase (DeWet *et al.*, 1987), secreted placental alkaline phosphatase (SEAP) (Lorenz *et al.*, 1991), β-lactamase (Moore *et al.*, 1997) and β galactosidase (Henthorn *et al.*, 1988).

Any change of said membrane receptor/reporter fusion protein as a result of adding the compound may be detected for example as a change in cellular localisation of the receptor/reporter fusion protein, or semi-quantitatively by the synthesis or degradation of said receptor/reporter fusion protein. Detection of any changes may easily be

carried out with cells placed on the surface of a microscope slide or the like. However, the assays of the present invention may conveniently be carried out on cells placed in a well of a microtitre plate or the like, such as a conventional 96-well plate.

A further modification to the assay described herein may be achieved for example by taking advantage of the route of internalisation and degradation of the PAR1 receptor. The protease activated receptor PAR1 mediates thrombin signalling. Unlike classic GPCRs such as the β_2-adrenoceptor which possess reversibly bound ligands, PAR1 (and other PAR family members), are activated following proteolytic cleavage of the N-terminus of the receptor protein by proteases such as thrombin to generate a new amino terminus that serves as a "tethered ligand", binding intramolecularly to the body of the receptor to initiate receptor signalling (Vu *et al.*, 1991a and 1991b). As with other GPCRs, following ligand activation PAR1 becomes rapidly phosphorylated and uncoupled from signalling. However, unlike classic GPCRs, PAR1 is sorted largely to the lysosomes to result in protein degradation (Trejo et al., 1998; Shapiro and Coughlin, 1998). Trafficking of activated PAR1 to the lysosomal rather than the endosomal compartment appears to be mediated entirely by the C-terminal tail of PAR1 (Trejo and Coughlin, 1999). The Substance P receptor (SPR) is activated by the peptide ligand substance P, internalised and recycled to the plasma membrane as observed for the WT β_2-adrenoceptor-GFP fusion

protein. However, exchanging the carboxyl cytoplasmic tail of the SPR for that of the PAR1 receptor resulted in the creation of an SPR/PAR1 fusion protein, which when activated by the ligand Substance P, became targeted to the lysosome for proteolytic degradation, rather than to the endosome for recycling to the plasma membrane (Trejo and Coughlin, 1999).

Thus it may be expected that a fusion protein comprising the substance P receptor, the β_2-adrenoceptor or any other GPCR, in which the cytoplasmic C-terminal tail of the receptor was replaced with the cytoplasmic C-terminal tail of the PAR1 receptor, would be internalised into lysosomes following agonist treatment to result in the degradation of the receptor protein. If this fusion protein also contained GFP, or any other reporter protein, fused in-frame onto the carboxyl terminus of the PAR1 receptor cytoplasmic C-terminal tail then agonist treatment would result in a loss of reporter signal as a result of lysosomal degredation of receptor protein. To assay for compounds with antagonist or inverse agonist activity cells would be pretreated with antagonist for a period of time prior to the addition of agonist. The antagonist would prevent agonist binding to the receptor, and so prevent agonist mediated degredation of receptor protein. Using GFP as the reporter protein this may be detected either by confocal microscopy of individual or groups of cells, or in microplate formats using a appropriate microplate fluorimeter. Using firefly luciferase as the reporter

protein receptor changes could be assessed following the assay of firefly luciferase activity using either microplate luminometry or by CCD imaging.

The present invention will now be further described by way of example only, with reference to the following figures which show:

Figure 1 shows plasma membrane location of WT β_2-adrenoceptor-GFP and internalisation in response to isoprenaline. The WT β_2-adrenoceptor-GFP was expressed stably in HEK293 cells and individual clones isolated. A patch of cells were imaged in the confocal microscope in the absence of agonist (A) and following addition of 10μM isoprenaline for 5 (B), 10 (C) and 30 (D) min.

Figure 2 shows recycling of WT β_2-adrenoceptor-GFP to plasma membrane following addition of alprenolol. A patch of HEK 293 cells stably expressing the WT β_2-adrenoceptor-GFP fusion protein were imaged in the confocal microscope in the absence of agonist (A) or following addition of isoprenaline (10μM) for 30 min (B). Following washing to remove isoprenaline, alprenolol (10μM) was added for 30 (C) or 40 (D) min.

Figure 3 shows expression of CAM β_2-adrenoceptor-GFP and upregulation by betaxolol. A CAM β_2-adrenoceptor-GFP construct was expressed stably in HEK293 cells and individual clones isolated. (a) Cells of a single clone were grown on glass coverslips in the absence (Upper panel) or presence (Lower panel) or betaxolol (10μM) for 24hr. These cells were then visualised. (b) Cells of this clone which were untreated or treated with betaxolol (10μM) and then washed were used to measure the specific binding of [^{3}H]DHA in intact cells ([^{3}H]DHA is a lipophillic antagonist which crosses the plasma membrane and thus provides a measure of total cell levels of β_2-adrenoceptor binding sites).

Figure 4 shows upregulation of CAM β_2-adrenoceptor-GFP by other β-adrenoceptor ligands. HEK 293 cells stably expressing the CAM β2-adrenoceptor-GFP expressing cells of Figure 3 were exposed to no ligand (A), carvedilol (B), Labetolol (C) or ICI118551 (D) (each at 1μM) for 24h. The cells were then imaged in the confocal microscope.

Figure 5 shows upregulation of CAM β_2-adrenoceptor-GFP but not WT β_2-adrenoceptor-GFP by betaxolol. Membrane fractions were prepared from HEK 293 cells stably expressing either the CAM β_2-adrenoceptor-GFP or the WT β_2-adrenoceptor-GFP fusion protein which had been maintained for 24 hours in the absence or presence of betaxolol (10μM) and subjected to SDS-PAGE. Following transfer to nitrocellulose, the

samples were immunoblotted using an polyclonal anti-GFP antibody to assess the level of fusion protein in these membranes.

Figure 6 shows internalisation of upregulated CAM β_2-adrenoceptor-GFP by isoprenaline (a) CAM β_2-adrenoceptor-GFP expressing cells were untreated (A) or exposed to betaxolol (10μM, 24h) (B-D). Following betaxolol treatment the cells were washed and isoprenaline (10μM) added for 0 (B), 10 (C) or 30 (D) min. (b) Cells as in Figure 6a were untreated, exposed to betaxolol (10μM, 24h) or exposed to betaxolol followed by further exposure to isoprenaline for 30min. Intact cells were then used to measure the specific binding of [^{3}H]CGP12177 ([^{3}H]CGP12177 is a hydrophillic ligand which does not penetrate the plasma membrane and in these conditions records only cell surface receptors).

Figure 7a shows the effect of various inverse agonists/antagonists on the level of fluorescence in CAM β_2-adrenoceptor-GFP determined by microtitre plate fluorimetery. Changes in fluorescence were measured on Spectrofluor Plus fluorimeter using cells plated in a 96 well plate. The graph shows the concentration responses to isoprenaline, betaxolol, alprenalol or sotalol after 22 h drug contact. Values are the mean percentages of basal of at least 3 experiments performed in duplicate ± SEM.

Figure 7b shows the concentration-dependence of the upregulation of CAM β_2-adrenoceptor-GFP by betaxolol determined by microtitre plate fluorimetry. Changes in fluorescence were measured on Spectrofluor Plus fluorimeter using cells plated in a 96 well plate. The graph shows a dose response curve to betaxolol at time 0 h (•) and after 22 h (▲). Values are the mean percentages of basal of 6 experiments performed in duplicate ±SEM.

Figure 7c shows the concentration dependence of the downregulation of β_2-adrenoceptor-GFP by Isoprenaline determined by microtitre plate fluorimetry. The graph shows a dose response curve to isoprenaline at time 0 h (•) and after 22 h (▲). Values are the mean percentages of basal of 6 experiments performed in duplicate ±SEM.

Figure 8 shows the concentration dependence of the upregulation by of CAM β_2-adrenoceptor-GFP by alprenolol. binding studies: CAM β_2-adrenoceptor-GFP expressing cells were untreated or exposed to varying concentrations of alprenolol for 24h. They were subsequently washed and intact cell specific binding of single concentrations of either [^{3}H]DHA or [^{3}H]CGP12177 measured to ascertain levels of total cell receptor and cell surface receptor respectively.

Figure 9

Location of mutations which imbue constitutive activation of phosphoinositidase C activity to the α_{1b}-adrenoceptor. A ribbon diagram of the primary diagram of the primary sequence of the hamster α_{1b}-adrenoceptor is displayed. The constitutively active mutant used herein (3CAM) has the following (R288K, K290H, A293L) alterations to the wild type sequence.

Figure 10

Upregulation of the 3CAM but not wild type hamster α_{1b}-adrenoceptor by sustained antagonist/inverse agonist challenge. Cells expressing either the 3CAM (10A) or wild type (10B) hamster α_{1b}-adrenoceptor grown on glass cover slips were treated with vehicle (a), phentolamine (b), WB4101 (c) or HV723 (d) (all at 1μM) for 24h. The cells were then visualised on a confocal microscope.
Equivalent studies were performed on plates of cells which were then washed and harvested. Membranes were prepared and the specific binding capacity of a single concentration (2 nM) of [^{3}H]prazosin was then assessed (Figure 10C).

Figure 11

Up-regulation of the WT and CAM α_{1b}-adrenoceptor/GFP fusion protein following stable expression in HEK 293 cells. The graphs show the effect on total cellular fluorescence of 22 hour treatment with (A) phenylephrine, (B) phentolamine, (C) WB 4101 and (D) HV 723. In all graphs ▲ represents

data obtained from wild type α_{1b}-adrenoceptor/GFP and ● represents data from CAM α_{1b}-adrenoceptor/GFP expressed in HEK 293 cells. All values are expressed as a percentage of the basal fluorescence and are the mean of at least 4 experiments performed in duplicate ±SEM.

Figure 12

Time course of up-regulation of CAM α_{1b}-adrenoceptor/GFP in NEK 293 cells. Graphs show the up-regulation of fluorescence caused with (A) phenylephrine, (B) WB 4101, (C) HV 723 and (D) phentolamine. The data represents one experiment performed in duplicate.

Figure 13

Schematic diagram of the β_2-adrenergic receptor/luciferase fusion protein construct.

Figure 14

Construction and conceptual use of a constitutively active β2-adrenoceptor linked to *Renilla reniformis* luciferase to identify antagonists at this receptor. The construct expressed in cells is treated with a ligand which binds to this receptor. This causes upregulation of the protein over time and thus higher levels of *Renilla reniformis* luciferase activity in the cell which can be monitored by standard procedures.

Figure 15

Concentration-dependent increases in levels of a constitutively active β2-adrenoceptor linked to *Renilla reniformis* luciferase. Varying concentrations of 3 ligands which bind to the β2-adrenoceptor were added to wells of a 96 well microtitre plate containing cells which stably express a constitutively active β2-adrenoceptor linked to *Renilla reniformis* luciferase. These plates were then incubated for 24hours after which time the media was pipetted off from each well.

50ul of phenol red free media was then added to each well plus 50ul of luc-lite solution (a commercial kit reagent which is optimised for Renilla luciferase activity and also contains a mild cell lysis component). Finally 50ul of 15uM coelenterazine in phenol red free media was added (to give a final concentration of 5uM). The plates were then assayed immediately on a top count luminometer to determine the light intensity in relative light units.

Figure 16

Laser scanning confocal images of HEK 293 cells stably transfected to express the PAR1mut/GFP fusion protein. Taken before (left hand image) and after 40mins incubation with 10μM TRAP (right hand image) A and B represent two different coverslips of cells.

Figure 17

Agonist down-regulation of the PAR1mut/GFP fusion protein following stable expression in HEK 293 cells. The bar graphs show the effects of 4 hours treatment with either (A) TRAP or (B) thrombin. All values are expressed as a percentage of the basal fluorescence and are the mean of 2 experiments performed in quadruplicate.

Materials and Methods I

[^{3}H]DHA (64 Ci/mmol) and [^{3}H]CGP-12177 (44 Ci/mmol) were purchased from (Amersham, UK). [^{3}H]adenine and [^{3}H]cAMP were purchased from Amersham International, Amersham, U.K. All reagents for cell culture were purchased from Life Technologies (Paisley, Strathclyde, U.K.). Receptor ligands were purchased RBI. All other reagents were purchased from Sigma or Fisons and were of the highest purity available.

Construction of GFP tagged forms of the β_2-adrenoceptor

Human wild type β_2- AR in pcDNA3 (MacEwan & Milligan 1996a) was amplified by PCR using a *Hind III*-FLAG forward primer, 5' AAAAAA AAGCTT GCCACC ATG GAC TAC AAG GAC GAC GAT GAT AAG GGG CAA CCC GGG AAC GGC 3', and a *Bam HI* reverse primer, 5' AAAAA GGATCC TCC CGC CAG CAG TGA GTC ATT TGT A 3'. This removed the stop codon and the initiating methionine (start codon) of β_2-WT-AR, with an initiator ATG being present in the N-terminally added FLAG™ epitope tag (ATG GAC TAC AAG GAC GAC GAT GAT AAG). The PCR product was digested with

Hind III and *Bam HI* and the resulting fragment ligated into pcDNA3 to generate a wild type B_2-AR/GFP construct. Sequence encoding amino acids 172-291 of WT B_2 receptor were restricted this construct using *Kpn I/Hpa I* and replaced by the equivalent region of the CAM β_2- AR (Samama *et al.*, 1993, 1994). A modified form of GFP (Zernicka-Goetz *et al.*, 1997) was also amplified by PCR using a *Bam HI* forward primer, 5' AAAAA GGATCC AGT AAA GGA GAA GAA CTT TTC 3', and an *Xba I* reverse primer, 5' TGCTCTAGATTATTTGTATAGTTCATCCATGCC 3'. This removed the initiating methionine of GFP and the resulting PCR product was digested and linked in frame to generate the CAM β_2- AR-GFP construct.

Transient and stable transfection of HEK293 cells

HEK293 cells were maintained in Minimum Essential Medium (MEM, Sigma) supplemented with 0.292 g/L L-glutamine, and 10% newborn calf serum at 37°C in a 5% CO_2 humidified atmosphere. Cells were grown to 60-80% confluence prior to transient transfection. Transfection was performed using LipofectAMINE reagent (Life Technologies, Inc.) according to manufacturers' instructions. To generate stable cell lines, two days after transfection cells were seeded/diluted and maintained in MEM medium supplemented with 1mg/ml Geneticin (Life Technologies, Inc.). Medium was replaced every 3 days with MEM medium containing 1mg/ml Geneticin. Clonal expression was initially examined by fluorescence microscopy for the GFP containing clones.

Selected clones expressing GFP and non-GFP tagged forms of the receptors were expanded and [^{3}H] ligand binding studies performed to assess the level of receptor expression.

Confocal laser scanning microscopy

Cells were observed using a laser scanning confocal microscope (Zeiss Axiovert 100) using a Zeiss Plan-Apo 63 x 1.40 NA oil immersion objective, pinhole of 35, and electronic zoom 1 or 3. The GFP was exited using a 488 nm argon/krypton laser and detected with 515-540 nm band pass filter. The images were manipulated with Zeiss LSM or MetaMorph software. Two different protocols for preparation of cells were used. When examining the time course of internalisation and recycling live cells were used. Cells were grown on glass coverslips and mounted on the imaging chamber. Cells were maintained in KRH buffer (see below) and temperature was maintained at 37°C. In other studies fixed cells were used. Cells on glass coverslips were washed with PBS and fixed for 20 min at room temperature using 4% paraformaldehyde in PBS/5% sucrose pH 7.2. After one wash with PBS coverslips were mounted on microscope slides with 40% glycerol in PBS.

[^{3}H]ligand binding studies

CAM β^2-AR-GFP cells were grown in 6 cm dishes and treated with or without 10μM betaxolol or various concentrations of alprenlol for 24 h. In some cases betaxolol treated cells were subsequently exposed to 10μM isoprenaline for 30 min.

After treatment the cells were washed 3 times with ice cold phosphate- buffered saline (PBS; 2.7mM KCl, 137mM NaCl, 1.5mM KH_2PO_4, 8mM Na_2HPO_4, pH 7.4). Cells were then detached from plates with PBS/0.5mM EDTA pelleted and resuspended in ice cold Krebs-Ringer-Hepes buffer (KRH; 130mM NaCl, 5mM KCl, 1.2mM $MgSO_4$, 1.2mM $CaCl_2$, 20mM HEPES, 1.2mM Na_2PO_4, 10mM glucose, 0.1% BSA; pH 7.4) buffer. After counting the cells in a hemocytometer approximately 100, 000 cells were added to each assay tube.

For binding studies a single concentration of [^{3}H] DHA (2nM) or [^{3}H] CGP-12771 (10nM) was used to measure total cell receptor and cell surface receptor respectively. Parallel studies with 10μM propranolol allowed assessment of non-specific binding. [^{3}H] DHA binding assays were performed at 30°C for 45 min and [^{3}H] CGP-12771 binding at 14°C for 2.5 hours in KRH buffer. All experiments were terminated by rapid filtration through Whatman GF/C filters followed by three washes with ice-cold TE (75mM Tris, 1mM EDTA; pH 7.4) buffer.

Intact cell adenylyl cyclase activity measurements

Were performed essentially as described by Wong (1994) and Mercouris *et al.* (1997). Cells were split into wells of a 12-well plate and the cells were allowed to reattach. Cells were then incubated in medium containing [^{3}H]adenine (1.5 μCi/well) for 16-24 h. The generation of [^{3}H]cAMP in response to treatment of the cells with various ligands and other reagents was then assessed. Results are presented as

the ratio of levels of [^{3}H]cAMP to total [^{3}H]adenine nucleotides (x 1000).

Immunoblotting studies

Electrophoresis and Immunoblot Analysis

A borate-based electrophoretic buffer system[Poduslo, J.F. (1981) Anal. Biochem. **114,** 131-139] was employed with some modifications. Briefly, the resolving polyacrylamide gel was made of 10% acrylamide, 0.0625% bisacrylamide, 0.1 M Tris (pH 8.5), 0.1 M boric acid, 0.0025 M EDTA, 0.1% SDS, 0.005% TEMED and 0.1% ammonium persulfate. The stacking gel was of the same composition except that it contained 4% acrylamide. The borate electrophoresis running buffer was composed of 0.1 M Tris, 0.1 M boric acid, 0.0025 M EDTA and 0.1% SDS (pH 8.5). Standard and borate electrophoresis were run for 1 h at 200 V and 150 V, respectively using a Mini Protean II gel kit (BIO-RAD, Hamel Hempstead, U.K.). After SDS-PAGE, proteins were electrophoretically transferred to nitrocellulose. The membrane was blocked for 1 h in 3% fat-free milk in PBS-T buffer (PBS containing 0.1% Tween 20). After a brief wash in PBS-T buffer, the membrane was incubated overnight at 4°C with an appropriate primary antibody diluted in PBS-T buffer containing 1% fat-free milk. A GFP polyclonal antibody (Clontech Laboratories, U.K.) was used for the detection of the constructs. The primary antibody was then removed and the blot washed extensively in PBS-T buffer. Subsequent incubation with secondary antibody (donkey anti-rabbit IgG conjugated with

horseradish peroxidase, Scottish Antibody Production Unit, Carluke Scotland) proceeded for 2 h at room temperature and after extensive washing in PBS-T buffer the blot was visualized by enhanced chemiluminescence ECL (Amersham). Quantitative analysis of specific bands was performed by scanning with an imaging densitometer GS-670 (BIORAD).

Studies in microtitre plates

Cells were seeded into black costar view plates the day before the experiment. On the day of the experiment the media was removed from the cells and drug added to the well in a final volume of 100 µl. The experiment was preformed in phenol red free F12 media containing 10% FCS. A Spectrafluor Plus fluorimeter was used to read the plates reading from the bottom at a gain of 100. A blank plate was initially read on the flourimeter and then the plates of cells were read at time 0 and after 22hrs incubation at 37°C with drug. Results were calculated by subtracting the blank plate from the fluorescence values obtained to control for plate autofluorescence.

Example 1 - Construction of GPCR/GFP fusion protein

A PCR based strategy was used to link a cDNA encoding a form of GFP with enhanced autofluorescence properties (Zernicka-Goetz *et al.*, 1997) in-frame with cDNAs encoding both the wild type β_2-adrenoceptor and a constitutively active mutant form of this GPCR, produced by replacement of a small segment of the distal end of the third

intracellular loop with the equivalent segment of the hamster α_{1B}-adrenoceptor. These were anticipated to encode single open reading frames in which the C-terminus of the GPCR was linked directly to the N-terminus of GFP. Following transient transfection of these constructs and visualisation on a fluoresecence microscope to confirm successful expression and autofluorescence, both of these constructs and the equivalent non-GFP tagged forms of the GPCRs were expressed stably in HEK293 cells. Individual clones were identified based on a combination of appropriate autofluorescence and specific binding of the β-adrenoceptor antagonist [^{3}H]dihydroalprenolol ([^{3}H] DHA) and subsequently expanded. In clones expressing the wild type β_2-adrenoceptor-GFP construct, confocal microscopy performed on intact cells grown on a glass cover slip demonstrated the bulk of the GFP-derived autofluorescence to be plasma membrane delineated (Figure 1). Addition of the β-adrenoceptor agonist isoprenaline (10^{-5} M) resulted in a time-dependent internalisation of the construct into discrete intracellular vesicles (Figure 1) as has previously been reported for such a construct (Barak *et al.*, 1997, Kallal *et al.*, 1998). The wild type β_2-adrenoceptor-GFP construct internalised following 30 min treatment with isoprenaline and could be recycled to the plasma membrane following removal of isoprenaline and its replacement by the β-adrenoceptor antagonist alprenolol (10^{-5}M) (Figure 2) which did not itself promote internalisation.

Although clones expressing the CAM β_2-adrenoceptor-GFP construct were also isolated these did not display the same level of GFP autofluoresence as the clones expressing the WT β_2-adrenoceptor-GFP construct. Such observations were consistent with routinely lower levels of steady state expression of the CAM β_2-adrenoceptor-GFP construct. This was confirmed by the lower levels of [^{3}H]DHA specific binding to membrane fractions isolated from these cells compared to clones expressing the wild type β_2-adrenoceptor-GFP construct. Furthermore, although clear plasma membrane-localised CAM β_2-adrenoceptor-GFP could be observed there appeared to be a greater fraction of the GFP autofluoresence located intracellularly than for the WT β_2-adrenoceptor-GFP (Figure 3a).

Example 2 - Ligand binding to GPCR/GFP fusion protein

The present applicants have previously postulated that sustained treatment of NG108-15 cells stably expressing the CAM β_2-adrenoceptor with the inverse agonist betaxolol can cause an increase in steady state levels of this GPCR. When cells expressing the CAM β_2-adrenoceptor-GFP construct were treated with betaxolol (24h, 10^{-5} M) and then visualised by confocal microscopy a marked increase in both plasma membrane delineated and intracellular fluoresence was observed (Figure 3a). Washing of the cells followed by an intact cell ligand binding experiment with [^{3}H]DHA confirmed upregulation of CAM β_2-adrenoceptor-GFP in response to betaxolol (Figure 3b). Upregulation of

fluoresence was also observed by treatment of the cells with a range of β_2-adrenoceptor inverse agonist/antagonists including ICI118551, labetolol, carvedilol, alprenolol and dihydroalprenolol (all at 10^{-5} M) (Figure 4). However, pharmacological selectivity of this effect was preserved as it was not recorded by treatment with the α_1-adrenoceptor antagonist prazosin or the α_2-adrenoceptor antagonist yohimbine (data not shown).

Sustained treatment of cells expressing wild type β_2-adrenoceptor-GFP with betaxolol or the other ligands described above failed to result in a significant upregulation of the construct as fluorescence intensity and distribution pattern was little modified by the drug treatments (data not shown). Upregulation of CAM β_2-adrenoceptor-GFP by betaxolol treatment could also be monitored in immunoblot experiments to confirm the effects seen by confocal microscopy. Membranes isolated from either wild type β_2-adrenoceptor-GFP or the CAM β_2-adrenoceptor-GFP expressing cells following maintenance in the presence or absence of betaxolol (10^{-5} M) for 24h were resolved by SDS-PAGE and the GPCR constructs detected by immunoblotting with an anti-GFP antibody. Clear upregulation of CAM β_2-adrenoceptor-GFP but not wild type β_2-adrenoceptor-GFP was observed (Figure 5).

Following betaxolol-induced upregulation of CAM β_2-adrenoceptor-GFP removal of this ligand, and its replacement by isoprenaline (10^{-5} M), resulted in a rapid internalisation of the construct into intracellular

punctate vesicles in a manner which was indistinguishable from that recorded above for wild type β_2-adrenoceptor-GFP (Figure 6a). [^{3}H]CGP-12177 is a hydrophillic β_2-adrenoceptor antagonist which is unable to cross the plasma membrane. Therefore in intact cell specific binding experiments it identifies only the cell surface population of the β_2-adrenoceptor. Such intact cell binding studies were performed on cells expressing CAM β_2-adrenoceptor-GFP, cells which had been pre-treated with betaxolol (24h, 10^{-5} M), and such cells after replacement of betaxolol with isoprenaline (10^{-5} M) for 30 min. These studies demonstrated that cell surface upregulated CAM β_2-adrenoceptor-GFP was largely internalised by agonist treatment (Figure 6b).

Upregulation of CAM β_2-adrenoceptor-GFP by sustained treatment with betaxolol and β-adrenoceptor antagonist/inverse agonist ligands could be detected and directly quantitated in a Spectrofluor Plus fluorimeter following seeding of cells into a 96 well microtitre plate. This allowed analysis of the concentration-dependence of CAM β_2-adrenoceptor-GFP upregulation with various inverse agoinst/antagonists after 22 h incubation with the compounds (Figure 7a). Betaxolol gave the clearest response (Figure 7b) producing an upregulation of the construct with an EC_{50} of 168(47-600)nM, a value in good accordance with the measured K_i of betaxolol to bind to this GPCR construct (MacEwan & Milligan 1996a). Treatment of the WT β_2-adrenoceptor-GFP fusion with betaxalol did not

result in any change in cellular fluorescence following either 1 h or 22 h of drug incubation. However, incubation of such cells with the agonist ligand isoprenaline for 22h resulted in a marked reduction of cellular fluorescence which upon quantification in the Spectrofluor Plus fluorimeter allowed an analysis of the concentration dependence of isoprenaline mediated changes in cellular fluorescence. Isoprenaline caused a decrease in cellular fluorescence an IC50 of 13(2.5-70) nM (Figure 7c). This contrasts with a reported EC_{50} of 5nM for the stimulation of cAMP by this drug at this receptor.

In summary this example shows that inverse agonist or neutral antagonist treatment of cells expressing a CAM β_2-adrenoceptor-GFP fusion construct results in an increase in membrane fluorescence as detected by confocal microscopy, and an increase in total cellular fluorescence as measured by microplate fluorimetry. The concentration dependence of these effects agrees with data obtained from traditional pharmacological studies thus validating the use of this approach for the characterisation of compounds which effect receptor function. The ability of inverse agonist or antagonist ligands to cause an increase in cellular fluorescence from cells expressing a CAM GPCR-GFP fusion allows for the provision of a microplate based fluorescence assay for new compounds with similar activity.

Agonist treatment of cells expressing the WT β_2-adrenoceptor-GFP fusion was observed to result in a decrease in membrane associated fluorescence and an

increase in fluorescence in intracellular vesicles which by co-immunolocalisation studies with an anti-transferrin antiserum are shown to be endosomes. The decrease in fluorescence observed by micrioplate fluorimetry following internalisation of the fusion protein may be due in part to receptor degradation but may also be due to a fluorescence quenching event as a consequence of receptor concentration within the acidic environment of the endosome compartment. However, this decrease in fluorescence caused by agonist ligands such as isoprenaline is concentration dependent and the half maximal drug concentrations required to cause this effect is in agreement with the values obtained in traditional second messenger analysis studies.

Thus the example discloses a novel screening system for compounds with either agonist, neutral antagonist or inverse agonist activity at the β_2-adrenoceptor in which compound activity results in a change in the fluorescence characteristics of cells expressing a β_2-adrenoceptor-GFP fusion protein. The change in the fluorescence characteristics can be measured by either a change in cellular localisation using the confocal microscope, or by a change in total cellular fluorescence as measured in a 96-place fluorimeter. Using confocal microscopy as the detection system, agonist ligand would cause an increase in cell surface fluorescence of the CAM GPCR/GFP fusion protein while antagonist/inverse agonist ligands cause an increase in internalisation of a WT GPCR/GFP fusion protein. Using microplate fluorimetry as the detection

system inverse agonist or antagonist ligands would cause an increase in total cellular fluorescence in cells expressing the CAM GPCR/GFP fusion protein while agonist ligands would cause a decrease in total cellular fluorescence in cells expressing a WT GPCR/GFP fusion protein.

Materials and Methods II

Construction of GFP-Tagged Forms of the 3CAMα_{1B}-adrenoceptor.

Production and subcloning C-terminally GFP tagged forms of wild type and 3CAM (R288K, K290H, A293L) forms of the hamster α_{1B}-adrenoceptor was performed in two separate stages. In the first step the coding sequence of a modified form of GFP was modified by polymerase chain reaction (PCR) amplification. Using the amino-terminal primer 5'-GGAAGGTACCAGTAAAGGAGAAGAACTT-3 the initiating Met of GFP was removed and both a *Kpn* I restriction site (underlined) and a 2-amino acid spacer (Gly-Asn) were introduced. Using the carboxy-terminal primer 5-TGCTCTAGATTATTTGTATAGTTCATCCATGCCATG-3' an *Xba* I restriction site (underlined) was introduced downstream of the stop codon of GFP. The amplified fragment of GFP digested with *Kpn* I and *Xba* I was subcloned into similarly digested pcDNA3 expression vector (Invitrogen). To obtain the α_{1B}-adrenoceptor-GFP fusion proteins, the coding sequence of each form of the α_{1B}-adrenoceptor was amplified by PCR. Using the amino-terminal primer 5' -

GACGGTACCTCTAAAATGAATCCCGAT-3', a *Kpn* I restriction site (underlined) was introduced upstream of the initiator Met. Using the carboxy-terminal primer 5'-GTCCCTGGTACCAAAGTGCCCGGGTG-3', a *Kpn* I restriction site (underlined) was introduced immediately upstream of the stop codon. Finally, the GFP construct in pcDNA3 was digested with *Kpn* I and ligated together with the PCR product of the α_{1B}-adrenoceptor amplification also digested with *Kpn* I. The open reading frames so produced represent the coding sequence of either the wild type or 3CAM α_{1B}-adrenoceptor-GFPs. Each was fully sequenced prior to its expression and analysis.

Transient and Stable Transfection of HEK293 Cells.

As previously described in Material and Methods I.

Preparation of membranes.

HEK293 cells stably expressing each of the α_{1B}-adrenoceptor-GFP fusion proteins were grown to confluence on 6cm dishes. Prior to harvesting, cells were washed twice with 4 ml of ice-cold TE buffer (10 mM Tris, 0.1 mM EDTA pH 7.5) and then scraped into 1 ml of the same buffer. Rupture of the cells was achieved with 25 strokes of a hand-held glass Dounce homogenizer on ice. The suspension was centrifuged at 16000 x g for 15 min and the resulting pellets resuspended in ice-cold TE buffer to final protein concentrations of 0.035-0.16mg/ml.

[^{3}H]Prazosin-binding experiments.

Binding experiments were initiated by the addition of 0.7-3.2 μg of membrane protein to an assay buffer (75 mM Tris/HCl (pH 7.5), 5 mM EDTA, 12.5 mM MgCl2 (buffer A) containing [^{3}H]prazosin (2 nM). Non-specific binding was determined in the presence of 10 μM phentolamine. Reactions were incubated for 30 min at 30°C and bound ligand was separated from free ligand by vacuum filtration through GF/B filters. The filters were washed twice with buffer A and bound ligand was estimated by liquid-scintillation spectrometry. Specific binding is displayed

Confocal laser scanning microscopy

As previously described in Materials and Methods I.

Example 3 - Upregulation of the 3CAM but not wild type hamster α_{1b}-adrenoceptor by sustained antagonist/inverse agonist challenge

Constructs encoding GFP protein linked in-frame with both wild type and 3CAM forms of the hamster α_{1b}-adrenoceptor were prepared as above (Materials and Methods II).

A more detailed description of the mutations in the wild type α_{1b}-adrenoceptor primary amino acid sequence that give rise to the various forms (R288K, K290H, A293L) of constitutively active mutant (CAM) α_{1b}-adrenoceptor is shown in Figure 9. Such constructs were used to transfect HEK293 cells followed by selection of transfected cells expressing

either the 3CAM or wild type α_{1b}-adrenoceptor as before (Materials and Methods I - transient and stable transfection of HEK293 cells). Such cells were used in [^{3}H] ligand binding studies to assess the level of receptor expression. Upregulation of fluoresence was observed on treatment of cells expressing the 3CAM α_{1b}-adrenoceptor/GFP fusion construct with a range of α_{1b}-adrenoceptor inverse agonist/antagonists (Figure 10A (b) - (d)). However, treatment of cells expressing wild type α_{1b}-adrenoceptor/GFP fusion construct with the same ligands, as for 3CAM above, failed to result in any significant upregulation of the construct, as fluorescence intensity and distribution pattern was little modified by the drug treatments (Figure 10B (b) - (d)) compared with vehicle treatments only (Figure 10B (a)).

Equivalent studies on both 3CAM and wild type α_{1b}-adrenoceptor with the α_{1b}-adrenoceptor antagonist prazosin are shown in Figure 10C. It can be seen that prazosin (PT) has no effect on the wild-type α_{1b}-adrenoceptor whereas it has the effect of upregulation of the mutant 3CAM form.

Example 4 - Ligand Up-regulation of CAM α_{1b}-adrenoceptor/GFP fusion protein in HEK 293 cells

Methods

HEK 293 cells stably expressing the wild type α_{1b}-adrenoceptor/GFP construct or the constitutively active mutant (CAM) α_{1b}-adrenoceptor/GFP fusion protein were produced as described previously in Materials and Methods II. These cell lines were used to investigate ligand up-regulation of the CAM α_{1b}-adrenoceptor/GFP fusion protein. Fusion protein upregulation was measured according to a gain in total cellular fluorescence in a plate based fluorimeter.

Cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% v/v foetal calf serum (FCS), 2mM L-glutamine and 1mg/ml geneticin (growth media; all reagents from Life Technologies) at 37°C in 5% CO_2 and 95% humidity. For experiments cells were seeded into black 96 well view plates (Costar) on the day before assay. On the day of assay the growth media was removed and replaced with phenol red free DMEM/F12 (1:1) medium containing 5% v/v FCS, 2mM L-glutamine in the presence of various concentrations of test compounds (phenylephrine, phentolamine, WB4101 and HV723) in a final volume 100μl. Cells were incubated at 37°C for 22 hours. After incubation fluorescence was detected using a Tecan Spectrafluor plus fluorimeter. To control for plate and media autofluorescence results were calculated by subtracting a

blank plate reading from the fluorescence values obtained in drug treated cells.

Results

HEK 293 cells stably expressing either the wild type α_{1b}-adrenoceptor/GFP fusion protein or the CAM α_{1b}-adrenoceptor/GFP were treated with a range of compounds to examine ligand stabilisation of fusion protein expression. Four compounds were chosen for this experiment, the agonist phenylephrine and three compounds previously shown to display inverse agonist activity at this receptor; WB 4101, HV723 and phentolamine. The level of fusion protein expression was determined by detecting changes in GFP expression by plate fluorimetry. All compounds tested had no effect on the expression level of the wild type α_{1b}-adrenoceptor/GFP fusion protein (Figure 11). However long term treatment (22hrs) of cells expressing the CAM α_{1b}-adrenoceptor/GFP fusion protein with these compounds caused a dose dependant up-regulation of fluorescence (Figure 11) with EC_{50} values of 407(15-10471)nM for phenylephrine, 676(195-2344)nM for WB 4101, 417(71-2455)nM for HV 723 and 170(32-891)nM for phentolamine.

Example 5 - Time course of up-regulation of CAM α_{1b}-adrenoceptor/GFP fusion protein in HEK 293 cells

Methods

The time course of ligand up-regulation of the CAM α_{1b}-adrenoceptor/GFP fusion protein was also investigated. In this study cells were seeded and treated with drug as previously described but fluorescence in the blank plate and the cell plates were read at various time points between 2-31 hours after drug addition.

Results

For all compounds tested there was a gradual increase in fluorescence over time. At all time points the EC_{50} for this dose related effect were unchanged (Figure 12). The magnitude of the response reached a maximum after about 23 hrs incubation with the compounds. After this time the response remained relatively constant.

Materials and Methods III

Construction of β_2-adrenergic receptor/Luciferase fusion proteins

Both β2-AR/RLuc and β2-AR/RLuc(CAM) were generated as follows. A β2-AR fragment was generated via PCR amplification of an existing β2-AR gene which had been cloned into pcDNA3, generation of the β2-AR(CAM) fragment was also via PCR amplification of a mutated version of β2-AR cloned into pcDNA3 plasmid vector. The mutations

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 August 2000 (24.08.2000)

PCT

(10) International Publication Number
WO 00/49416 A3

(51) International Patent Classification[7]: G01N 33/68, C12N 15/62, C07K 14/72

(21) International Application Number: PCT/GB00/00585

(22) International Filing Date: 18 February 2000 (18.02.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9903767.3 18 February 1999 (18.02.1999) GB

(71) Applicant *(for all designated States except US)*: **UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW** [GB/GB]; Gilbert Scott Building, University Avenue, Glasgow G12 8QQ (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **MILLIGAN, Graeme** [GB/GB]; 2/1 64 Lauderdale Gardens, Hyndland, Glasgow G12 9QW (GB). **REES, Edward, Stephen** [GB/GB]; 30 Youngs Rise, Welwyn Garden City, Herts AL8 6RU (GB).

(74) Agents: **McCALLUM, William, Potter** et al.; Cruikshank & Fairweather, 19 Royal Exchange Square, Glasgow G1 3AE (GB).

(81) Designated States *(national)*: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

(88) Date of publication of the international search report:
15 February 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/49416 A3

(54) Title: RECEPTOR ASSAY FOR DETECTING AN EFFECT TEST COMPOUNDS HAVE ON A PARTICULAR MEMBRANE RECEPTOR

(57) Abstract: The present invention relates to receptor/reporter fusion protein based assays for detecting an effect test compounds have on a particular membrane receptor, as well as to receptor/reporter fusion proteins for use in such assays and compounds identified by the assays as having interesting/useful effects. Suitable membrane receptors are growth factor receptors, cytokine receptors, ion channels and integrins including any subtypes, mutants, homologs and chimeric forms of such receptors. The assay is particularly suited to studying G-protein coupled receptors (GPCRs).

INTERNATIONAL SEARCH REPORT

Intern. nal Application No
PCT/GB 00/00585

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/68 C12N15/62 C07K14/72

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N C12N C12P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 30715 A (ISACOFF EHUD Y ;SIEGAL MICAH S (US); UNIV CALIFORNIA (US); CALIFOR) 16 July 1998 (1998-07-16) page 2, line 15 -page 3, line 4 page 3, line 30 -page 4, line 2 page 5, line 5 -page 6, line 25 page 8, line 24 -page 9, line 15 page 11, line 9-21 page 13, line 13 -page 14, line 11 page 24, line 27 -page 26, line 13 claims 1-51; figure 1B; examples 1,2	1-3,5, 7-11, 14-17, 20,24, 26-31
Y		2,6,12, 13,18, 19, 21-23,25

	-/--	

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
14 November 2000	17. 11. 00

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Goetz, M

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 20931 A (US HEALTH ;HTUN HAN (US); HAGER GORDON L (US)) 12 June 1997 (1997-06-12) page 6, line 7 -page 9, line 27 page 15, line 15 -page 16, line 13 page 19, line 4 -page 21, line 2 page 30, line 21 -page 32, line 12 figure 3A	1-29
Y	BARAK L S ET AL: "Internal trafficking and surface mobility of a functionally intact beta2-adrenergic receptor-green fluorescent protein conjugate" MOLECULAR PHARMACOLOGY,US,BALTIMORE, MD, vol. 2, no. 51, 1 February 1997 (1997-02-01), pages 177-184, XP002076352 ISSN: 0026-895X cited in the application	1-29
X	the whole document	30,31
X,P	DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; December 1999 (1999-12) MCLEAN ALISON J ET AL: "Visualizing differences in ligand regulation of wild-type and constitutively active mutant beta2-adrenoceptor-green fluorescent protein fusion proteins." Database accession no. PREV200000102798 XP002152838 abstract & MOLECULAR PHARMACOLOGY, vol. 56, no. 6, December 1999 (1999-12), pages 1182-1191, ISSN: 0026-895X	1-29

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 00/00585

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 30,31
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 30,31

Present claims 30-31 relate to an extremely large number of possible compounds, including a plethora of yet unknown, thus hypothetical agonists/antagonists. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only some of the compounds claimed having an agonist/antagonist activity on a membrane receptor. In the present case, claims 30 and 31 so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those compounds as recited in the examples.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter nal Application No
PCT/GB 00/00585

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9830715 A	16-07-1998	AU 5090498 A	03-08-1998
WO 9720931 A	12-06-1997	AU 1283497 A	27-06-1997
		CA 2239951 A	12-06-1997

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/12 C12N15/62 C12N5/10 C07K14/435 C07K14/72
C12Q1/02 G01N33/50 G01N33/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PROC. NATL.ACAD SCI., vol. 92, no. 25, 5 December 1995, NATL. ACAD SCI.,WASHINGTON,DC,US;, pages 11899-11903, XP002029556 H. OGAWA ET AL.: "Localization, trafficking, and temperature-dependence of the Aequorea green fluorescent protein in cultured vertebrate cells" cited in the application	29,30, 39, 41-44, 46,48, 51-54,57
Y	see the whole document	45,49

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family,

1

Date of the actual completion of the international search	Date of mailing of the international search report
16 April 1997	25. 04. 97

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016	Hornig, H



FIG.5

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	THIRTY-FIFTH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY, WASHINGTON, D.C., USA, DECEMBER 9-13, 1995. MOLECULAR BIOLOGY OF THE CELL 6 (SUPPL.). 1995. 313A. ISSN: 1059-1524, November 1995, XP000670313 MACARA I G ET AL: "Real-time detection of ligand-induced nuclear transport using a glucocorticoid receptor - green fluorescent protein fusion construct."	29,30, 37,38, 41-46, 48, 51-54,57
Y	abstract no. 1818 see abstract	49

X	THIRTY-FIFTH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY, WASHINGTON, D.C., USA, DECEMBER 9-13, 1995. MOLECULAR BIOLOGY OF THE CELL 6 (SUPPL.). 1995. 232A. ISSN: 1059-1524, November 1995, XP002029557 HTUN H ET AL: "GFP - GR: A model system for studying cytoplasm-to-nuclear translocation and nuclear architecture in cultured living cells."	29,30, 39, 41-46, 48, 51-54,57
Y	abstract no. 1345 see abstract	49

Y	NATURE, vol. 373, 23 February 1995, MACMILLAN JOURNALS LTD., LONDON,UK, pages 663-664, XP002029558 R. HELM ET AL.: "Improved green fluorescence" cited in the application see the whole document	45

Y	TRENDS IN GENETICS, vol. 11, no. 8, August 1995, ELSEVIER SCIENCE LTD., AMSTERDAM, NL, pages 320-323, XP002029559 D.C. PRASHER: "Using GFP to see the light" see the whole document	45

Y	TIBS TRENDS IN BIOCHEMICAL SCIENCES, vol. 20, November 1995, pages 448-455, XP000606919 CUBITT A B ET AL: "UNDERSTANDING, IMPROVING AND USING GREEN FLUORESCENT PROTEINS" cited in the application see page 451, left-hand column, line 47 - middle column, line 7	45

	-/--	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 33, 25 November 1991, pages 22075-22078, XP000611463 CHAKRABORTI P K ET AL: "CREATION OF "SUPER" GLUCOCORTICOID RECEPTORS BY POINT MUTATIONS IN THE STEROID BINDING DOMAIN" cited in the application see the whole document	49
A	WO 95 07463 A (UNIV COLUMBIA ;WOODS HOLE OCEANOGRAPHIC INST (US); CHALFIE MARTIN) 16 March 1995 see the whole document	1-58
A	WO 95 21191 A (WARD WILLIAM ;CHALFIE MARTIN (US)) 10 August 1995 see the whole document	1-58
A	NATURE, vol. 369, 2 June 1994, pages 400-403, XP002003600 WANG S ET AL: "IMPLICATIONS FOR BCD MRNA LOCALIZATION FROM SPATIAL DISTRIBUTION OF EXU PROTEIN IN DROSOPHILA OOGENESIS" see the whole document	1-58
A	SCIENCE, vol. 263, 11 February 1994, AAAS,WASHINGTON,DC,US, pages 802-805, XP002003599 M. CHALFIE ET AL.: "Green fluorescent protein as a marker for gene expression" see the whole document	1-58
P,X	PROC. NATL.ACAD SCI., vol. 93, no. 10, 14 May 1996, NATL. ACAD SCI.,WASHINGTON,DC,US;, pages 4845-4850, XP002029560 H. HTUN ET AL.: "Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera" see the whole document	1-58
P,X	JOURNAL OF CELL BIOLOGY 133 (5). 1996. 985-996. ISSN: 0021-9525, June 1996, XP000670316 CAREY K L ET AL: "Evidence using a green fluorescent protein- glucocorticoid receptor chimera that the RAN-TC4 GTPase mediates an essential function independent of nuclear protein import." see the whole document	29,30, 37,38, 41-46, 48, 51-54,57

1

INTERNATIONAL SEARCH REPORT

rnational application No.
PCT/US 96/19516

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.: 31-36
because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although these claims are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9507463 A	16-03-95	US 5491084 A	13-02-96
		AU 7795794 A	27-03-95
		CA 2169298 A	16-03-95
		EP 0759170 A	26-02-97
WO 9521191 A	10-08-95	NONE	